Computed Tomography (CT)

Researchers are studying whether 68Ga-FAPI PET/CT scans can be a new effective way to evaluate axillary lymph nodes after neoadjuvant treatment in women with breast cancer. This observational study focuses on patients who have clinically positive axillary lymph nodes and have undergone treatment before surgery. The goal is to understand if this imaging method can better detect remaining cancer in lymph nodes compared to traditional methods. Participants will have a 68Ga-FAPI PET/CT scan after completing at least three courses of neoadjuvant therapy and before surgery. This scan is being evaluated for its ability to detect residual disease in the lymph nodes without being affected by blood glucose levels, offering potentially clearer imaging. The study will observe participants without altering their treatment, focusing on this imaging test. During the study, participants will undergo the PET/CT scan, and researchers will track how well the scan predicts residual cancer in the lymph nodes after treatment. They will measure the sensitivity and specificity of the scan up to the time of surgery, and follow participants for up to three years to see how well the scan predicts invasive disease-free survival and overall survival. Participants' usual care will continue throughout the study, which starts in August 2024 and ends in June 2026.

This research aims to assess the diagnostic value of a new PET/CT imaging probe called 68Ga-C1, which specifically targets the CAIX protein found in about 95% of clear cell renal cell carcinomas. The study will also investigate the safety, tolerability, and radiation exposure from 68Ga-C1. Researchers will compare this new imaging method with the standard 18F-FDG PET/CT scan in Chinese patients who have unclear kidney masses or confirmed clear cell renal cell carcinoma. Participants with suspected or confirmed clear cell renal cell carcinoma will receive an intravenous injection of 68Ga-C1 at a dose of 0.05-0.10 mCi/kg, followed by PET imaging. They will also undergo a whole-body 18F-FDG PET/CT scan within one week. This approach allows direct comparison of the two imaging techniques in the same patients. During the study, participants will have PET/CT scans with both imaging agents to evaluate tumor detection and characteristics. Researchers will measure diagnostic accuracy, radiation dosimetry, and quantitative uptake of 68Ga-C1 over one year. Correlation with tumor pathology will also be assessed. The study will monitor safety and tolerability throughout, with the overall participation lasting at least one year.

Researchers are investigating the diagnostic potential of a new molecular imaging probe called gallium 68-labelled fibroblast-activation protein inhibitor (68Ga-FAPI) in detecting various malignant tumors. Fibroblast-activation protein (FAP) is commonly found in cancer-associated fibroblasts within tumor tissue and plays a role in tumor growth and spread. This study aims to confirm the advantages of 68Ga-FAPI over traditional imaging methods like 18F-fluorodeoxyglucose (18F-FDG) PET/CT, which can sometimes give false positive or negative results in certain cancers. Participants who have undergone whole-body 18F-FDG PET/CT scans for suspected or confirmed malignancies, particularly tumors with low FDG uptake such as glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases, will receive a whole-body 68Ga-FAPI PET/CT scan within one to four weeks. The 68Ga-FAPI is injected intravenously with a dose based on body weight, and imaging is performed 20 to 60 minutes after injection. This interventional study evaluates how well 68Ga-FAPI PET/CT can diagnose and stage malignant tumors. During the study, participants will undergo the 68Ga-FAPI PET/CT scan and be monitored for diagnostic sensitivity and specificity over three years. Researchers will also assess the prognostic value of FAPI PET parameters up to one year post-treatment, evaluate therapeutic response within one week after completion of therapy, and explore correlations between PET imaging and histopathological biomarkers within four weeks of the scan. The study includes informed consent and follow-up assessments to understand the imaging method's overall effectiveness in managing cancer.

Researchers are evaluating the use of 68Ga-grazytracer PET imaging to help diagnose pseudoprogression in lung cancer patients after immunotherapy. Pseudoprogression is difficult to distinguish with current clinical methods, which often require follow-up observations that may not meet clinical needs. This study aims to assess the effectiveness and feasibility of this novel imaging agent, which targets granzyme B to show the activity of cytotoxic T cells in tumor areas. This observational study uses 68Ga-grazytracer PET/CT scans to visualize and semi-quantitatively measure granzyme B concentration in lung cancer lesions that have enlarged or developed new lesions after immune checkpoint inhibitor treatment. The study follows patients for 4-8 weeks, up to a maximum of 12 weeks, to evaluate the diagnostic performance of this imaging method in detecting pseudoprogression. Participants will undergo PET/CT imaging and be monitored over the follow-up period to assess changes and outcomes. Researchers will collect data on diagnostic accuracy and safety during this time. The study includes adult lung cancer patients aged 18 to 75 years who meet specific clinical criteria and have a life expectancy of at least six months. Total participation duration varies with the follow-up period, and patient compliance with study requirements is monitored throughout.

Researchers are evaluating a new imaging method using 68Ga-MY6349 PET/CT to detect Trop-2 expression in tumor lesions of patients with solid tumors. This study aims to compare the effectiveness of this new PET radiotracer with the standard 18F-FDG PET/CT imaging to identify patients who may benefit from Trop-2 targeted imaging. The study is observational and involves patients with various types of malignant tumors, either newly diagnosed or previously treated. Participants receive a single intravenous injection of the 68Ga-MY6349 tracer and then undergo PET/CT imaging within a set timeframe. They also undergo standard-of-care imaging with 18F-FDG PET/CT either for initial assessment or to detect tumor recurrence. The uptake of the tracer in tumors is measured by the maximum standard uptake value (SUVmax) and compared visually to the standard imaging results. During the study, researchers will assess the feasibility of using 68Ga-MY6349 PET/CT for non-invasive evaluation of Trop-2 expression in tumors. Participants will have both imaging tests and their tumor lesions will be documented and analyzed. The primary focus is on imaging accuracy and tracer uptake within one week. This study is sponsored by The First Affiliated Hospital of Xiamen University and involves adults aged 18 years or older with solid tumors.

Researchers are evaluating a new dual-target imaging agent called 68Ga-RM26-RGD for PET/CT scans in patients with breast, brain, and prostate cancers that express specific receptors (GRPR and integrin αvβ3). This study aims to improve tumor detection by comparing this agent with conventional 18F-FDG and single-target imaging agents, addressing limitations of current imaging methods in detecting tumors with low 18F-FDG uptake or variable receptor expression. Participants will undergo PET/CT scans using intravenous injections of 68Ga-RM26-RGD and one of the comparator agents (18F-FDG, 68Ga-RM26, or 68Ga-RGD) within a two-week period. The dosages for these agents are approximately 1.8-2.2 MBq/kg. Each patient receives scans with both agents to compare imaging performance directly. During the study, researchers will assess diagnostic accuracy and dosimetry of 68Ga-RM26-RGD over about one year. Participants will have multiple PET/CT scans and related evaluations to monitor uptake of the imaging agents in tumors. The study includes safety and diagnostic performance monitoring throughout the participation period.

Researchers are evaluating a new imaging approach using 68Ga-XACP3 PET/CT to detect tumor lesions in men with prostate cancer. This study compares the diagnostic performance of 68Ga-XACP3 PET/CT with the current standard imaging method, 68Ga-PSMA PET/CT, aiming to improve detection of initial or recurrent prostate cancer lesions. The study is led by The First Affiliated Hospital of Xiamen University. Participants receive a single intravenous injection of both 68Ga-XACP3 and 68Ga-PSMA radiotracers, followed by PET/CT imaging within a designated time frame. The study records tumor uptake using maximum standard uptake value (SUVmax) and counts the number of positive tumor lesions detected by both imaging methods. Diagnostic accuracy of 68Ga-XACP3 will be calculated and compared to 68Ga-PSMA. During the study, participants undergo both PET/CT scans and clinical assessments to evaluate tumor detection. Researchers will measure diagnostic efficacy over one year, focusing on the number of lesions identified and SUV values. Participants must provide informed consent, and safety and imaging results will be monitored throughout the study period, which runs until October 2027.

Researchers are studying a new type of scan called FAPI-PET/CT to see how well it detects metastases in patients with advanced gastric cancer. The study aims to find out if this scan can better identify cancer spread, leading to changes in treatment plans such as avoiding unnecessary surgeries or shifting to comfort-focused care. It also evaluates whether the scan causes less burden for patients compared to current methods. Participants will receive the standard care for gastric cancer and undergo one additional FAPI-PET/CT scan, where a small amount of [18F]-FAPI-74 is given intravenously about 60 minutes before a PET/CT scan lasting around 20 minutes. The results from this scan will help doctors decide on further tests or surgery needed. The study monitors changes in diagnosis and treatment decisions based on the scan. During the study, participants will complete questionnaires taking about 4 hours total and spend approximately 2 hours for the extra scan. Researchers will measure outcomes such as changes in treatment intent, diagnostic work-up, scan accuracy, incidental findings, patient burden, quality of life, and safety over about one year. Follow-up includes quality of life assessments and cost evaluations at multiple time points after staging.

This research aims to evaluate how well spectral CT scans perform compared to conventional CT scans in assessing the treatment response after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). The focus is on determining the diagnostic accuracy of spectral CT in identifying nonviable tumor lesions and residual viable cancer following TACE. The study is led by Zhongda Hospital and includes patients aged 18 to 75 years with early to intermediate stage HCC. Participants undergo contrast-enhanced spectral CT scans 4 to 8 weeks after TACE treatment. Those assessed as having a complete response on conventional CT may then have surgical resection, hepatic arteriography, or contrast-enhanced MRI within a short time frame. If these procedures are not planned, patients receive imaging follow-up with CT or MRI every 3 months for at least one year. Another group includes patients who receive spectral CT within 7 days before liver tumor surgery following TACE downstaging therapy. During the study, researchers collect imaging data to evaluate the diagnostic performance of spectral CT. Participants are monitored through scheduled imaging and clinical assessments, with follow-up lasting at least one year from enrollment. The main outcomes measured are how accurately spectral CT identifies nonviable HCC lesions and detects residual viable tumors after TACE treatment. The study does not involve interventional treatments but focuses on observational imaging assessment.

Researchers are conducting a pilot study to evaluate a new portable 0.7 Tesla (T) MRI brain scanner developed at the Center for Magnetic Resonance Research (CMRR). This study aims to demonstrate the human brain imaging capabilities of this innovative device, which is designed to be compact and more accessible compared to traditional MRI machines. The study uses a unique high-temperature superconducting magnet-based scanner that is lightweight, weighing only 400 kg, and requires no cryogens. The device allows participants to sit normally with clear sightlines to the room and produces lower noise during scanning, enhancing comfort during the procedure. Participants will undergo brain imaging using the portable 0.7 T MRI scanner. Researchers will assess the quality of the images obtained on the first day of scanning as the primary outcome. The study includes healthy volunteers aged 18 and older who can consent for themselves and have no contraindications for MRI. The total duration and follow-up details are not specified.